Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D COURTNEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1346215001
CMS profile
241794
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,871.04

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,375.00 1
Food and Beverage $296.51 3
Travel and Lodging $199.53 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $3,794.02 4
GENZYME CORPORATION $77.02 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D COURTNEY

NPI 1346215001 · CMS profile ID 241794

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346215001?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D COURTNEY, NPI 1346215001, CMS profile ID 241794. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346215001?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KEVIN D COURTNEY, NPI 1346215001, CMS profile ID 241794. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346215001?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KEVIN D COURTNEY, NPI 1346215001, CMS profile ID 241794, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1346215001?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $3,871.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $77.0208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049779063 CMS
Novartis Pharmaceuticals Corporation $127.6002/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991434123 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $3,375.0002/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423509 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $91.8902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423511 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $199.5302/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993423513 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,403.72 5
PY2023 $3,871.04 5
PY2024 $106.06 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $952,128.23 48
PY2024 Principal investigator $1,027,466.83 39
PY2023 Principal investigator $1,564,725.74 11
PY2022 Principal investigator $215,055.09 10
PY2021 Principal investigator $236,546.50 15
PY2020 Recipient $72.50 1
PY2020 Principal investigator $366,307.58 47
PY2019 Principal investigator $417,827.61 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,340.00 12/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409546
Principal investigator 1 Janssen Research & Development, LLC $2,049.00 12/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409903
Principal investigator 1 Janssen Research & Development, LLC $3,864.00 12/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409931
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 11/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409909
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410022
Principal investigator 1 Janssen Research & Development, LLC $2,835.00 11/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410035
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 11/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410153
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 11/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410260
Principal investigator 1 Janssen Research & Development, LLC $17,736.00 11/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409925
Principal investigator 1 Janssen Research & Development, LLC $7,354.00 11/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410224
Principal investigator 1 Janssen Research & Development, LLC $1,309.00 10/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409512
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 09/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410004
Principal investigator 1 Janssen Research & Development, LLC $4,824.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409950
Principal investigator 1 Janssen Research & Development, LLC $1,809.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410212
Principal investigator 1 Janssen Research & Development, LLC $185.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410346
Principal investigator 1 Janssen Research & Development, LLC $11,222.00 09/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410217
Principal investigator 1 Amgen Inc. $2,207.27 08/08/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy No dispute reported 06/30/2026 1246650888
Principal investigator 1 Janssen Research & Development, LLC $3,864.00 07/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410078
Principal investigator 1 Janssen Research & Development, LLC $3,679.00 07/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409308
Principal investigator 1 Janssen Research & Development, LLC $185.00 06/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409788
Principal investigator 1 Janssen Research & Development, LLC $1,059.00 06/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410340
Principal investigator 1 Janssen Research & Development, LLC $2,835.00 05/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409320
Principal investigator 1 Janssen Research & Development, LLC $1,273.00 05/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409998
Principal investigator 1 Janssen Research & Development, LLC $185.00 05/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409453
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 05/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409944
Principal investigator 1 Janssen Research & Development, LLC $22,086.00 05/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410201
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 04/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409328
Principal investigator 1 Janssen Research & Development, LLC $3,679.00 04/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409560
Principal investigator 1 Janssen Research & Development, LLC $8,900.00 04/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409574
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 04/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409628
Principal investigator 1 Janssen Research & Development, LLC $603.00 04/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409838
Principal investigator 1 Janssen Research & Development, LLC $8,900.00 04/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410134
Principal investigator 1 Janssen Research & Development, LLC $14,400.00 04/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409506
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409582
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,754.00 03/24/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer No dispute reported 06/30/2026 1190306187
Principal investigator 1 AstraZeneca UK Limited $89,147.90 03/12/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL SCHOOL
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185549177
Principal investigator 1 Janssen Research & Development, LLC $9,611.00 03/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410276
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,121.32 02/18/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190305809
Principal investigator 1 Janssen Research & Development, LLC $24,229.00 02/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409361
Principal investigator 1 Amgen Inc. $167,398.45 02/13/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy No dispute reported 06/30/2026 1246650872
Principal investigator 1 Janssen Research & Development, LLC $18,401.00 02/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175410108
Principal investigator 1 Janssen Research & Development, LLC $274.00 01/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409377
Principal investigator 1 Janssen Research & Development, LLC $8,900.00 01/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS SOUTHWESTER N MEDICAL CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175409708
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,001.35 01/15/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306189
Principal investigator 1 Novartis Pharmaceuticals Corporation $304,999.60 01/15/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190306191
Principal investigator 1 AstraZeneca UK Limited $65,900.75 01/14/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER HEPATOLOGY
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185549179
Principal investigator 1 Celgene Corporation $4,196.40 01/08/2025 Non-covered Recipient Entity
University Of Texas Southwestern Medical School
A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer No dispute reported 06/30/2026 1222305878
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,754.19 01/07/2025 Non-covered Recipient Entity
UT SOUTHWESTERN MEDICAL CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305807